PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models
Pairing HER3-DXd with the PARP inhibitor olaparib increased DNA damage, induced apoptosis, and slowed tumor progression in vivo in preclinical non-small cell lung cancer models. The post PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models appeared first on GEN - Genetic Engineering and Biotechnology News .
A recent preclinical study published in Cell Reports Medicine has demonstrated that pairing the HER3-targeting antibody-drug conjugate HER3-DXd with the PARP inhibitor olaparib could boost the antitumor activity in non-small cell lung cancer (NSCLC) models. The combination therapy was found to increase DNA damage, induce apoptosis, and slow tumor progression in vivo, without being limited to specific genetic mutations in the cancer cells.
Additionally, the treatment activated the cGAS-STING pathway, which can enhance innate immune signaling and natural killer cell-mediated tumor killing. The researchers suggest that HER3 could serve as a potential biomarker for identifying patients who may benefit from this type of treatment. While the findings are promising, the study remains preclinical, and further research is needed to determine the safety and efficacy of this combination therapy in human patients.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
